UNI-MB - logo
UMNIK - logo
 
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • O-2 CHARACTERIZATION OF SER...
    Arnold, Jorge; Díaz, Luis Antonio; Idalsoaga, Francisco; Valverde, María Ayala; Ayares, Gustavo; Rivera, Paula; Solís, Nancy; Arrese, Marco; Arab, Juan Pablo

    Annals of hepatology, March 2023, 2023-03-00, 2023-03-01, Letnik: 28
    Journal Article

    Alcohol consumption is among the five main factors responsible for the burden of disease and mortality. It is associated with changes in serum bile acids, and in recent years, extracellular vesicles (EV´s) and their Cargo have shown special interest in various lines of research due to their role in intercellular communication. This study aimed to characterize the serum levels of bile acids, changes in their composition, extracellular vesicles and their cargo in alcohol-associated liver disease (ALD). Prospective cohort, years 2019-2021. They were divided into four groups; control group, alcohol-associated hepatitis (AH), alcohol-related cirrhosis, and alcohol use disorder (AUD). Measurement of serum bile acids and C4 was performed through Liquid Chromatography /Tandem Mass Spectrometry, serum measurement of FGF19 and the serum concentration of extracellular vesicles through NTA (nanoparticle tracking analysis) and their cargo of bile acids. A greater concentration of total bile acids was measured in the AUD group (1366.28 ng/ml) compared to the control group (552.42 ng/ml) (p = 0.003). The concentration of chenodeoxycholic acid is higher in the group of patients with AH (734.23 ng/ml) (p=0.04). The EV´s concentration is higher in the HA groups (1.292 E^11 ± 6.4E^10 particles/ml) and in AUD (9.9E^10+ 4.9E^ particles/ml) (p=0.005). It was possible to analyze the Cargo of BA in exosomes with proportional differences between the groups. Serum bile acids, both in concentration and composition, are modified in patients with AUD and HA, respectively; both present a higher concentration of exosomes, which could be a hepato-specific, dynamic and potentially prognostic biomarker in subjects with ALD.